Modification of reported antibiotic susceptibility testing according to the EUCAST recommendations: Evaluation of the appropriateness of antibiotic prescriptions in a university hospital - 01/11/25
, F. Meyer a, M. Simon b, c, E. Jeanbert c, B. Demore a, b, A. Charmillon dHighlights |
• | The impact of “susceptible, increased exposure” EUCAST classification on antibiotic prescriptions was evaluated. |
• | Meropenem prescriptions for P. aeruginosa decreased subsequent to modification of post-antibiotic susceptibility testing. |
• | There was more reliance on infectiologists’ opinions on updated post-antibiotic susceptibility testing. |
• | Despite the changes in antibiotic susceptibility testing, high-dose antibiotic prescriptions remained suboptimal. |
• | Selective reporting on antibiotic susceptibility testing effectively contributed to antimicrobial stewardship. |
Abstract |
Objectives |
In January 2022, EUCAST guidelines recommending replacement of the “intermediate” category with a “susceptible, increased exposure” (SFP) category were implemented in our hospital. We aimed to assess the impact of these changes on antibiotic prescriptions for Pseudomonas aeruginosa and Staphylococcus aureus infections.
Methods |
This retrospective before–after study included adult inpatients with monobacterial infections between March–August 2021 (BEFORE) and March–August 2022 (AFTER). Antibiotic use and relevance were compared. Meropenem was masked when imipenem was categorized as SFP.
Results |
We included 240 antibiotic susceptibility tests (195 patients). Infectious disease consultations increased significantly during implementation (53.0 % vs. 28.9 %, p = 0.0005). Meropenem prescriptions for P. aeruginosa declined (13.8 %–6.2 %), while high-dose regimens for SFP antibiotics likewise decreased (50.0 %–35.4 %). Overall, prescription appropriateness remained high (>92 %).
Conclusion |
The introduction of SFP reporting was associated with increased ID consultation and a trend toward reduced broad-spectrum use, highlighting a need for targeted prescriber education.
Le texte complet de cet article est disponible en PDF.Keywords : Anti-bacterial agents, Drug resistance, Antibiotic susceptibility testing, Bacteriology, Meropenem
Plan
Vol 55 - N° 7
Article 105130- novembre 2025 Retour au numéro
Article précédent
- Amoxicillin/clavulanate activity against bacteria isolated in severe community-acquired pneumonia: a retrospective study (sCAP)
- A. Sarr, M.A. Matta, F. Kayembe, A. Depontfarcy, M. Monchi, S. Diamantis
- Retrospective analysis of discharge antibiotic selection and 30-day readmission rate for community acquired pneumonia
- Nick Hartwig, Eric Wombwell
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?